



Anti-VEGF Intravitreal Injection Therapy Verification Form

Blue Cross and Blue Shield of Illinois reviews voluntary requests for pre-service recommended clinical review (predetermination) of anti-VEGF (vascular endothelial growth factor) intravitreal injections for certain conditions of the eye when services are proposed for our **commercial non-HMO** and **Federal Employee Program®** members.

Recommended clinical review determinations are made based on medical necessity criteria outlined in the following medical policies:*

- [BCBSIL's Medical Policies](#) – OTH903.026, OTH903.027, OTH903.041, OTH903.043, OTH903.044
- [FEP® Medical Policies](#) – 5.90.026, 5.90.029, 5.90.05, 5.90.052

**Note: This list of policies may change. Please check the websites for any other policies that may apply.*

The purpose of this therapy verification form is to help you prepare prior to submitting a voluntary request for recommended clinical review to BCBSIL.

Instructions

This form includes important reminders and a Provider Questionnaire. Think of it as a worksheet to help clarify your voluntary request for recommended clinical review.

1. **Review medical policy information.** Remember, before you begin, review the applicable BCBSIL or FEP medical policy for coverage criteria that may apply.
2. **Answer all questions in the appropriate Section(s) below.** This will help clarify Continuation Therapy and/or Initial Therapy details.
3. **Gather all necessary medical record documentation, as appropriate, to support your request.**
4. **Submit this completed form and supporting medical record documentation to BCBSIL, along with your voluntary request for recommended clinical review.** See below for electronic options to submit voluntary recommended clinical review requests and supporting documentation. **Electronic options are preferred to help expedite your request.** Alternatively, you can download and complete a [paper recommended clinical review form](#) and fax your information to BCBSIL.
 - Commercial non-HMO member requests at BCBSIL – [Use BlueApprovRSM](#) or the [Availity® Attachments tool](#) on the Availity Essentials portal.
 - FEP member requests – Use the [Availity® Attachments tool](#).

Note: Failure to include necessary medical record documentation may result in delays or hinder the ability to confirm medical necessity of your request.

Provider Questionnaire

Section A – Continuation Therapy

1. Is the member currently receiving the requested medication through a previously authorized pharmacy or medical benefit? Yes No
2. What is the current dosing supported by an authoritative source?
3. Is the member benefiting from therapy as evidenced by disease stability or disease improvement? Yes No

Section B – Initial Therapy

1. Has the member tried and failed, or has a reason to avoid intravitreal injection(s) of bevacizumab (Avastin™) as an anti-VEGF therapy been determined? Yes No
2. Please include a brief explanation regarding your response above.

Review the applicable BCBSIL or FEP medical policy for coverage criteria that may apply.

Availity is a trademark of Availity, LLC., a separate company that operates a health information network to provide electronic information exchange services to medical professionals. Availity provides administrative services to BCBSIL. BCBSIL makes no endorsement, representations, or warranties regarding third party vendors and the products and services they offer. Trademarks are the property of their respective owners.